CY1107901T1 - Μεθοδος προσδιορισμου για ασθενεια alzheimer - Google Patents
Μεθοδος προσδιορισμου για ασθενεια alzheimerInfo
- Publication number
- CY1107901T1 CY1107901T1 CY20081100267T CY081100267T CY1107901T1 CY 1107901 T1 CY1107901 T1 CY 1107901T1 CY 20081100267 T CY20081100267 T CY 20081100267T CY 081100267 T CY081100267 T CY 081100267T CY 1107901 T1 CY1107901 T1 CY 1107901T1
- Authority
- CY
- Cyprus
- Prior art keywords
- beta
- alzheimer
- determination method
- preclinical
- disease
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
- G01N2333/4701—Details
- G01N2333/4709—Amyloid plaque core protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Urology & Nephrology (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Peptides Or Proteins (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US31322101P | 2001-08-17 | 2001-08-17 | |
| US31322401P | 2001-08-17 | 2001-08-17 | |
| US33498701P | 2001-10-23 | 2001-10-23 | |
| EP02766022A EP1416965B8 (en) | 2001-08-17 | 2002-08-16 | Assay method for alzheimer's disease |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1107901T1 true CY1107901T1 (el) | 2013-09-04 |
Family
ID=27405654
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20081100267T CY1107901T1 (el) | 2001-08-17 | 2008-03-07 | Μεθοδος προσδιορισμου για ασθενεια alzheimer |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP1416965B8 (enExample) |
| JP (2) | JP4511830B2 (enExample) |
| AT (1) | ATE381346T1 (enExample) |
| CA (1) | CA2457145C (enExample) |
| CY (1) | CY1107901T1 (enExample) |
| DE (1) | DE60224200T2 (enExample) |
| DK (1) | DK1416965T3 (enExample) |
| ES (1) | ES2295401T3 (enExample) |
| PT (1) | PT1416965E (enExample) |
| WO (1) | WO2003015617A2 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL151378A0 (en) | 2000-02-24 | 2003-04-10 | Univ Washington | Humanized antibodies that sequester amyloid beta peptide |
| US7771722B2 (en) | 2001-08-17 | 2010-08-10 | Eli Lilly And Company | Assay method for alzheimer's disease |
| DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
| US7575747B2 (en) | 2003-02-10 | 2009-08-18 | Applied Molecular Evolution | Aβ binding molecules |
| EP1480041A1 (en) * | 2003-05-22 | 2004-11-24 | Innogenetics N.V. | Method for the prediction, diagnosis and differential diagnosis of Alzheimer's disease |
| GB0519398D0 (en) * | 2005-09-23 | 2005-11-02 | Antisoma Plc | Biological materials and uses thereof |
| BRPI0619249A2 (pt) | 2005-11-30 | 2011-09-20 | Abbott Lab | anticorpos anti-globulÈmeros-aß, frações que se ligam a antìgeno destes, hibridomas correspondentes, ácidos nucléicos, vetores, células hospedeiras, métodos de produzir os ditos anticorpos, composições compreendendo os ditos anticorpos, usos dos ditos anticorpos e métodos de usar os ditos anticorpos |
| PT1976877E (pt) | 2005-11-30 | 2014-04-29 | Abbvie Inc | Anticorpos monoclonais contra proteína beta-amilóide e suas utilizações |
| US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
| CA2675847C (en) | 2007-01-18 | 2014-12-30 | Eli Lilly And Company | Pegylated a.beta. fab |
| EP2124952A2 (en) | 2007-02-27 | 2009-12-02 | Abbott GmbH & Co. KG | Method for the treatment of amyloidoses |
| WO2010093001A1 (ja) * | 2009-02-13 | 2010-08-19 | 国立大学法人大阪大学 | アルツハイマー病の診断方法および診断薬 |
| KR101531949B1 (ko) | 2009-12-11 | 2015-06-26 | 아라클론 바이오테크, 에스.엘. | 아밀로이드 베타 펩티드의 개선된 검출 방법 및 시약 |
| EP2558494B1 (en) | 2010-04-15 | 2018-05-23 | AbbVie Inc. | Amyloid-beta binding proteins |
| CN105348387B (zh) | 2010-08-14 | 2020-08-25 | Abbvie 公司 | β淀粉样蛋白结合蛋白 |
| EP2511296A1 (en) | 2011-04-12 | 2012-10-17 | Araclón Biotech, S. L. | Antibody, kit and method for determination of amyloid peptides |
| IL245703B (en) * | 2013-11-20 | 2022-07-01 | Univ Iowa Res Found | Methods and compositions for treating amyloid deposits |
| CN109187981A (zh) * | 2018-08-01 | 2019-01-11 | 万东山 | 一种快速检测β-淀粉样蛋白的量子点免疫层析试纸条与应用 |
| KR102496845B1 (ko) * | 2018-08-08 | 2023-02-08 | 서울대학교산학협력단 | 진단 지표로서 베타-아밀로이드 수준과 함께 혈장 타우 수준을 사용하는 알츠하이머병의 진단 및 치료 방법 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1298436B1 (en) * | 1992-10-26 | 2010-07-14 | Elan Pharmaceuticals, Inc. | Methods for the identification of Beta-amyloid peptide (BAP) release inhibitor compounds |
| US7964192B1 (en) * | 1997-12-02 | 2011-06-21 | Janssen Alzheimer Immunotherapy | Prevention and treatment of amyloidgenic disease |
| TWI239847B (en) * | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
| US6730778B2 (en) * | 1997-12-19 | 2004-05-04 | Pharmacia And Upjohn Company | Human sel-10 polypeptides and polynucleotides that encode them |
| IL151378A0 (en) * | 2000-02-24 | 2003-04-10 | Univ Washington | Humanized antibodies that sequester amyloid beta peptide |
-
2002
- 2002-08-16 EP EP02766022A patent/EP1416965B8/en not_active Expired - Lifetime
- 2002-08-16 WO PCT/US2002/026321 patent/WO2003015617A2/en not_active Ceased
- 2002-08-16 JP JP2003520382A patent/JP4511830B2/ja not_active Expired - Lifetime
- 2002-08-16 ES ES02766022T patent/ES2295401T3/es not_active Expired - Lifetime
- 2002-08-16 AT AT02766022T patent/ATE381346T1/de active
- 2002-08-16 DE DE60224200T patent/DE60224200T2/de not_active Expired - Lifetime
- 2002-08-16 DK DK02766022T patent/DK1416965T3/da active
- 2002-08-16 PT PT02766022T patent/PT1416965E/pt unknown
- 2002-08-16 CA CA2457145A patent/CA2457145C/en not_active Expired - Fee Related
-
2008
- 2008-03-07 CY CY20081100267T patent/CY1107901T1/el unknown
-
2009
- 2009-09-09 JP JP2009208372A patent/JP5162553B2/ja not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1416965B1 (en) | 2007-12-19 |
| JP2004538477A (ja) | 2004-12-24 |
| CA2457145A1 (en) | 2003-02-27 |
| EP1416965A4 (en) | 2005-11-02 |
| PT1416965E (pt) | 2008-04-01 |
| ATE381346T1 (de) | 2008-01-15 |
| CA2457145C (en) | 2010-12-21 |
| ES2295401T3 (es) | 2008-04-16 |
| JP2010044078A (ja) | 2010-02-25 |
| EP1416965A2 (en) | 2004-05-12 |
| DE60224200D1 (de) | 2008-01-31 |
| DK1416965T3 (da) | 2008-05-05 |
| HK1061960A1 (en) | 2004-10-15 |
| WO2003015617A3 (en) | 2004-01-29 |
| DE60224200T2 (de) | 2008-07-10 |
| JP5162553B2 (ja) | 2013-03-13 |
| WO2003015617A2 (en) | 2003-02-27 |
| JP4511830B2 (ja) | 2010-07-28 |
| EP1416965B8 (en) | 2008-02-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT1416965E (pt) | Método de ensaio para a doença de alzheimer | |
| EP1944040A3 (en) | Assay method for Alzheimer's disease | |
| DK1351707T3 (da) | Fremgangsmåder til behandling af autoimmunsygdomme hos et individ og in vitro-diagnostiske analyser | |
| PT830170E (pt) | Sistema de infusao automatica com calculador de razao de dose | |
| ATE512224T1 (de) | Rekonstituierter menschlicher anti-hm.1 antikörper | |
| DE59102225D1 (de) | Ultraschall-Kontrastmittel, Verfahren zu ihrer Herstellung und Verwendung derselben als Diagnostika und Therapeutika. | |
| ATE461941T1 (de) | Antikörper gegen alzheimer spezifische tau proteine mit abnormaler konformation | |
| ES2138729T3 (es) | Metodos de diagnostico de la preeclampsia. | |
| WO2006036291A3 (en) | Antibodies directed against amyloid-beta peptide and methods using same | |
| DE69626683D1 (de) | Verfahren zur feststellung von antipolymerantikörper und diagnosetestsatz zur feststellung von siliconabhängigen krankheiten | |
| DE69333076D1 (de) | Test und behandlung von demyelinierenden krankheiten wie multiple sklerosis | |
| ATE318328T1 (de) | Diagnostika und therapeutika für osteoporose | |
| ATE159300T1 (de) | Monoklonale antikörper gegen menschliches ige | |
| EP1017845A4 (en) | Diagnostic test for alzheimer's disease | |
| BR0314713A (pt) | Processos e reagentes para o tratamento de doenças e distúrbios associados com nìveis aumentados de citocinas pró-inflamatórias | |
| FI973469A0 (fi) | Menetelmä tekijän IX valmistamiseksi biologisista lähteistä | |
| WO2004003563A3 (en) | Diagnostic and therapeutic use of ensadin-0581 gene and protein for neurodegenerative diseases | |
| WO2002016636A3 (en) | Diagnostic and therapeutic use of a caveolae-associated integral membrane protein for alzheimer's disease and related neurodegenerative disorders | |
| WO2004001422A3 (en) | Diagnostic and therapeutic use of ras-gtpase-activating sh3-domain-binding protein 2 (g3bp2) for neurodegenerative diseases | |
| BR0113646A (pt) | Tratamento de distúrbios inflamatórios | |
| AU2002211577A1 (en) | Protecting therapeutic compositions from host-mediated inactivation | |
| WO2004038411A3 (en) | Diagnostic and therapeutic use of ensadin-0289 gene and protein for neurodegenerative diseases | |
| AU2002366555A1 (en) | Diagnostic for early stage alzheimer's disease | |
| AU2003208857A1 (en) | Diagnostic and therapeutic use of caps | |
| DE50214523D1 (de) | Nukleotidträger zur diagnose und therapie oraler erkrankungen |